MONDAY, Feb. 13, 2023 (HealthDay News) — The COVID-19 antiviral treatment Paxlovid continues to work against Omicron subvariants BA.4 and BA.5, new research shows. Researchers decided to study Paxlovid’s impact against severe illness and death because doctors have fewer treatment options for high-risk patients as the virus evolves. “We areContinue Reading

Who benefits most from COVID boosters? Protection is strongest for people over 60, a new study finds. Younger people might still want to consider a booster, to protect people around them. Read more Paxlovid remains potent against Omicron COVID cases. The antiviral continued to protect against hospitalization and death inContinue Reading